Beam Therapeutics Inc [BEAM] stock prices are up 1.49% to $22.50 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BEAM shares have gain 3.12% over the last week, with a monthly amount drifted -3.89%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, H.C. Wainwright started tracking the stock with Buy rating on July 23, 2024, and set its price target to $80. On January 29, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $40 on the stock. BofA Securities downgraded its rating to a Neutral but stick to its price target of $35 on December 15, 2023. Jefferies downgraded its rating to a Hold and reduced its price target to $30 on December 08, 2023. Leerink Partners downgraded its rating to Market Perform for this stock on October 20, 2023, and downed its price target to $20. In a note dated October 20, 2023, Cantor Fitzgerald downgraded an Neutral rating on this stock.
The stock price of Beam Therapeutics Inc [BEAM] has been fluctuating between $18.18 and $49.50 over the past year. Currently, Wall Street analysts expect the stock to reach $64.2 within the next 12 months. Beam Therapeutics Inc [NASDAQ: BEAM] shares were valued at $22.50 at the most recent close of the market. An investor can expect a potential return of 185.33% based on the average BEAM price forecast.
Analyzing the BEAM fundamentals
The Beam Therapeutics Inc [NASDAQ:BEAM] reported sales of 352.57M for trailing twelve months, representing a drop of -41.48%. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -0.52%, Pretax Profit Margin comes in at -0.4%, and Net Profit Margin reading is -0.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.16 and Total Capital is -0.17. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.96 points at the first support level, and at 21.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.87, and for the 2nd resistance point, it is at 23.24.
Ratios To Look Out For
It’s worth pointing out that Beam Therapeutics Inc [NASDAQ:BEAM]’s Current Ratio is 5.81. In addition, the Quick Ratio stands at 5.81 and the Cash Ratio stands at 1.65. Considering the valuation of this stock, the price to sales ratio is 5.26, the price to book ratio is 2.17.
Transactions by insiders
Recent insider trading involved Ciaramella Giuseppe, President, that happened on Oct 14 ’24 when 51110.0 shares were sold. Officer, Giuseppe Ciaramella completed a deal on Oct 14 ’24 to buy 0.1 million shares. Meanwhile, Officer Burrell Terry-Ann bought 0.19 million shares on Oct 07 ’24.
